Corifact approved for treating congenital factor XIII deficiency

CSL Behring announced that Corifact (factor XIII concentrate [human] injection) has been approved for the routine prophylactic treatment of congenital factor XIII deficiency. Corifact is a fibrin-stabilizing factor concentrate that provides both A- and B-subunits to protect against FXIII deficiency. The concentrated formula is dosed, depending on the patient's weight, to maintain trough factor XIII levels between 5–20%of normal.

Corifact is available as lyophilized powder in a single-use vial.

For more information call (800) 504-5434 or visit www.corifact.com.